# FDA 483 - Sanofi Pasteur Inc. - Unknown Date

Source: https://www.keypedia.com/records/483/sanofi-pasteur-inc/ecac1e06-2dca-4ed9-bfc8-8d7c8ebd3481

> FDA 483 for Sanofi Pasteur Inc. on Unknown Date. Product: biologics. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Sanofi Pasteur Inc.
- Product Type: biologics
- Office Name: Division of Clinical Evidence and Analysis 1 (Clinical Policy and Quality)
- Summary: An FDA inspection of Sanofi Pasteur, Inc. in Swiftwater, PA, a vaccine manufacturer, revealed two significant observations. The firm failed to follow procedures for YF-VAX production operations, specifically regarding conveyor speed adjustments during lyophilizer unloading. Additionally, the firm did not adequately document or evaluate cycle failures associated with a specific line, with no investigation initiated to assess trends or impact on process validation.

## Related Documents

- [483 - 2024-01-26](https://www.keypedia.com/records/483/sanofi-pasteur-inc/49eddef0-a693-47ad-966c-ecda5ffefdd7)
- [EIR - 2018-10-26](https://www.keypedia.com/records/eir/sanofi-pasteur-inc/db1cb36f-bcff-41df-ae66-4e0afc24e462)
- [EIR - 2023-04-22](https://www.keypedia.com/records/eir/sanofi-pasteur-inc/6bcbc538-aa67-495c-a379-27e1e0ecd60c)
- [483 - 2006-04-28](https://www.keypedia.com/records/483/sanofi-pasteur-inc/bde995cd-46d2-484f-a76e-e96d0512702d)
- [483 - 2023-04-22](https://www.keypedia.com/records/483/sanofi-pasteur-inc/e60a0f17-6ec3-4dd0-8048-0d2095627241)

## Related Officers

- [investigator](https://www.keypedia.com/people/solomon-yimam/043f0fe2-e686-4b94-b1fa-8be44359db29)
- [investigator](https://www.keypedia.com/people/christian-d-lynch/3b2748d3-3800-4538-939d-71a33dca0b2d)
- [issuing_officer](https://www.keypedia.com/people/dino-feigelstock/462413b8-21a9-409f-bda0-349b2ac8e08b)

Company: https://www.keypedia.com/companies/sanofi-pasteur-inc/94f5ecde-ae72-47f6-b6b7-ca9126ef544f

Office: https://www.keypedia.com/offices/division-of-clinical-evidence-and-analysis-1-clinical-policy-and-quality/5f95da17-30bb-423f-b892-5ea041823fbd